Document:

Exhibit 10.1

 

 

	 	June
    26, 2015	 

[Investor]

[Address]

[Address]

Ladies
and Gentlemen:

Reference
is made to the Common Stock Purchase Warrant, dated December 2, 2014, that you received from Guided Therapeutics, Inc. (the “Company”)
in connection with its public offering of securities on that date (the “Warrant”). By signing this letter agreement
you agree to the following:

1.                 
You shall exchange the Warrant for two new warrants, each in form attached hereto (the “New Warrants”). The
first New Warrant will have an exercise price of $0.09 per share, and the second New Warrant will have an exercise price of $0.11
per share. Other than exercise price, each New Warrant will have identical terms, and each New Warrant will be exercisable for
the same number of shares of the Company’s common stock as the Warrant, at any time beginning December 2, 2015 until December
2, 2020. Delivery of the New Warrants is contingent upon return of a duly executed copy of this letter agreement along with the
original Warrant (or an affidavit of lost warrant, in form provided by the Company upon request). The Company agrees to use its
commercially reasonable efforts to register the shares of its common stock underlying the New Warrants on a resale registration
statement that it expects it will be required to file pursuant to a customary registration rights agreement entered into connection
with a proposed capital-raising transaction (the “Proposed Transaction”).

2.                 
You shall duly execute and deliver the attached Amendment to Securities Purchase Agreement, amending the Securities Purchase Agreement,
dated November 26, 2014, to remove the restriction on Variable Rate Transactions (as defined therein) and the restriction from
undertaking a reverse or forward stock split or reclassification of the Company’s common stock.

3.                 
As additional consideration for the above, within three business days of the Company’s receipt of the Warrant, the Company
will issue to you $________ in shares of the Company’s common stock, valued as of the closing price of the Company’s
common stock of the effective date of this letter agreement (the “Additional Shares” and, with the New Warrants
and the shares of the Company’s common stock issuable upon exercise of the New Warrants, the “Consideration”).
[1] The Additional Shares will be issued free of restrictive legends. You agree not to transfer the shares (other than
to an affiliate) at any time prior to (i) 90 days from the date of issuance or (ii) the effectiveness of a registration statement
registering for resale any or all of the securities issued in the Proposed Transaction.

1
The aggregate dollar amount of the Additional Shares will be 7.7778% of the amount you invested in the December 2014 public offering.
For example, if you invested $450,000 in the December 2014 public offering, you would receive $35,000 in Additional Shares ($450,000
x 0.077778 = $35,000).

 

    	 

    	 

    

4.                 
Upon receipt of the Consideration, you relinquish all rights, title and interest you have in the Warrant (including any claims
you may have against the Company related thereto) and assign the same to the Company. You understand and acknowledge that upon
the Company’s acceptance of the Warrant, the Warrant will be canceled.

5.                 
You represent and warrant that (a) you have the full power and authority to exchange the Warrant for the Consideration; (b) the
Warrant is free and clear of all security interests, liens, restrictions, charges, encumbrances, conditional sales agreements
or other obligations relating to the sale or transfer thereof and not subject to any adverse claims; (c) you are an “accredited
investor” as that term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended,
you can bear the economic risk of an investment in the Consideration, and you have such knowledge and experience in financial
and business matters and your are capable of evaluating the merits and risks of investment in the Consideration; (d) you have
had the opportunity to review the Company’s current business prospects, financial condition and operating history as set
forth in the Company’s filings with the Securities and Exchange Commission; and (e) you have had the opportunity to ask
questions and receive answers from the Company regarding all the information you consider necessary or appropriate for deciding
whether to invest in the Consideration.

6.                 
You acknowledge that the issuance of the Consideration will not be registered under the Securities Act of 1933, as amended, that
the Consideration is being offered and sold to you in reliance on specific exemptions from the registration requirements of U.S.
federal and state securities laws, and that the Company is relying in part upon the truth and accuracy of, your representations,
warranties, agreements, acknowledgments and understandings set forth in this letter agreement, in order to determine the availability
of such exemptions and your eligibility to acquire the Consideration. You further acknowledge that the Consideration may not be
offered for sale, sold, transferred or assigned (a) in the absence of (i) an effective registration statement for the Consideration
under the Securities Act of 1933, as amended, or (ii) an opinion of counsel to the holder (if requested by the Company), in a
form reasonably acceptable to the Company, that registration is not required under said act or (b) unless sold or eligible to
be sold pursuant to Rule 144 or Rule 144A under said act. Notwithstanding the foregoing, the Company acknowledges that the Consideration
may be pledged in connection with a bona fide margin account or other loan or financing arrangement secured by the Consideration.

7.                 
Upon request, you shall execute and deliver any additional documents deemed by the Company to be necessary or desirable to complete
the exchange of the Warrant for the Consideration.

[
remainder of page intentionally blank ]

 

 

    	 

    	 

    

 

If
this letter agreement correctly reflects the terms agreed by you and the Company, please sign a copy of this letter agreement
in the space provided below and return it, along with the Warrant, to the Company.

Very
truly yours,

 

 

GUIDED
THERAPEUTICS, INC.

By:
/s/ Gene Cartwright

Name: Gene Cartwright

Title: CEO

 

Agreed to
as of June 26, 2015:

 

[Investor]

 

 

By:  ____________________________

Name:

Title:Exhibit
10.2

amendment
to securities purchase agreement

This
Amendment to Securities Purchase Agreement (this “Agreement”) is dated as of June __, 2015 and is between
GUIDED THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the other parties identified on the
signature pages hereto.

On
November 26, 2014, the parties entered into a securities purchase agreement (the “Purchaser Agreement”) providing
for the purchase of certain securities of the Company. Capitalized terms used in this Agreement without definition have the meanings
assigned to them in the Purchase Agreement.

The
Purchase Agreement currently prohibits the Company, until 18 months after the Closing Date, from effecting or entering into an
agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction (the “Variable Rate Transaction Restriction”). The
Purchase Agreement also currently prohibits the Company, until the one year anniversary of the Closing Date, from undertaking
a reverse or forward stock split or reclassification of the Common Stock without the prior written consent of the Purchasers holding
a majority in interest of the Shares except under certain circumstances (the “Capital Change Restriction”).

The
parties believe it is in their mutual best interests to maximize the Company’s flexibility in its capital raising efforts
and, to that end, desire to amend the Purchase Agreement to remove the Variable Rate Transaction Restriction and the Capital Change
Restriction.

Therefore,
the parties agree as follows:

		1.	Amendments
                                         to Purchase Agreement. Section 4.12(b) of the Purchase Agreement, which provides
                                         for the Variable Rate Transaction Restriction, and Section 4.15 of the Purchase Agreement,
                                         which provides for the Capital Change Restriction, are hereby deleted in their entirety.

		2.	Effect
                                         of Amendment. Except as set forth expressly in Section 1, all terms of the Purchase
                                         Agreement shall be and remain in full force and effect, and shall constitute the legal,
                                         valid, binding and enforceable obligations of the parties to the Purchase Agreement.

		3.	Condition
                                         Precedent. In accordance with Section 5.5 of the Purchase Agreement, the amendment
                                         set forth in Section 1 shall become effective upon execution and delivery of this Agreement
                                         by Purchasers who purchased at least 67% in interest of the Shares based on the initial
                                         Subscription Amounts thereunder.

		4.	Counterparts.
                                         This Agreement may be executed in any number of counterparts and each of such counterparts
                                         will for all purposes be deemed to be an original, and all such counterparts will together
                                         constitute but one and the same instrument.

[
SIGNATURE page follows ]

 

    	 

    	 

    

The
parties are signing this Agreement as of the date stated in the introductory clause..

	 	GUIDED
    THERAPEUTICS, INC.

    

    

    By:/s/ Gene S. Cartwright

    Name: Gene S. Cartwright

    Title: President
	 	 
	 	PURCHASER

                                         

        

        ____________________________________

        

        

By:_________________________________

Name:

Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]